While Iwai et al (2018) showed that T‐025 also inhibited DYRK1A, a kinase that has been postulated as a tumor suppressor in some cancers (Liu et al, 2014), they point out that DYRK1A depletion in cancer cells blunt T‐025 treatment effects. This evidence concerns the gene DYRK1A and cancer.